|
gptkbp:instanceOf
|
gptkb:chemical_compound
stimulant
|
|
gptkbp:ATCCode
|
gptkb:N06BA01
|
|
gptkbp:boilingPoint
|
203 °C
|
|
gptkbp:CASNumber
|
156-34-3
|
|
gptkbp:chemicalFormula
|
C9H13N
|
|
gptkbp:chirality
|
true
S-enantiomer of amphetamine
|
|
gptkbp:component
|
gptkb:Adderall
gptkb:Benzedrine
gptkb:Evekeo
|
|
gptkbp:contraindication
|
gptkb:cardiovascular_disease
hypertension
glaucoma
hyperthyroidism
history of drug abuse
|
|
gptkbp:discoveredBy
|
gptkb:Lazăr_Edeleanu
|
|
gptkbp:discoveredIn
|
1887
|
|
gptkbp:drugClass
|
stimulant
anorectic
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:halfLife
|
11-14 hours
|
|
gptkbp:hasEnantiomer
|
D-amphetamine
|
|
gptkbp:hasInChIKey
|
KWTSXDURSIMDCE-SECBINFHSA-N
|
|
gptkbp:hasSMILES
|
CC(CC1=CC=CC=C1)N
|
|
gptkbp:hasUNII
|
CK833KGX7E
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
L-amphetamine
|
|
gptkbp:isomerOf
|
amphetamine
|
|
gptkbp:IUPACName
|
(S)-1-phenylpropan-2-amine
|
|
gptkbp:legalStatus
|
controlled substance (varies by country)
|
|
gptkbp:mechanismOfAction
|
increases synaptic concentrations of dopamine and norepinephrine
releases monoamines
|
|
gptkbp:meltingPoint
|
34-36 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
135.21 g/mol
|
|
gptkbp:PubChem_CID
|
5362440
CHEBI:4846
|
|
gptkbp:routeOfAdministration
|
oral
intranasal
|
|
gptkbp:sideEffect
|
anxiety
headache
increased heart rate
insomnia
dry mouth
|
|
gptkbp:synonym
|
gptkb:levoamphetamine
(S)-amphetamine
|
|
gptkbp:usedFor
|
appetite suppression
treatment of ADHD
treatment of narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:selegiline
|
|
gptkbp:bfsLayer
|
7
|